// App-Quantinova.ai

1392 : Sequencing-Based Minimal Residual Disease Assessment In T-Cell Malignancies: T-Cell Prolymphocytic Leukemia Case Study

Researchers

Presenter

  • Katherine Sutherland

Principal Investigators

  • Katherine A Kong

  • Aaron C. Logan

  • Malek Faham

  • David B. Miklos

Medical Centers

  • Stanford School of Medicine, Stanford, CA

  • Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA

Locations

  • United States

Companies

  • Sequenta, Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Post-transplant lymphoproliferative disorder

  • T-cell prolymphocytic leukemia

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Lympho proliferative disease

  • Mantle cell lymphoma

  • Lymphomas

  • Solid malignancies

  • Acquired immunodeficiency syndrome

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

  • Peripheral blood mononuclear cell

  • T cell receptor beta locus

  • T cell receptor delta locus

  • White Blood Cell

  • T-cell receptor

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Cyclosporine eent

  • Alemtuzumab

  • fludarabine tablet

  • Prednisone

  • Melphalan

  • Rituximab

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved